Clinical Trial

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

Study acronym: CEA+RC-BCG
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2015-03-25; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Active, Not Recruiting 2017-03-01
Trial Details
NCT Number NCT02403505
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare
Conditions Rectal Cancer
Enrollment 20 participants
Start Date 2021-12-28
Primary Completion 2026-11-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-28